Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Emerging Future Treatments for Vitiligo: JAK Inhibitors, IL-15 Targeting, and siRNA Therapies
Description
The speaker outlined emerging vitiligo treatments built from mechanistic research showing that CD8 T cells drive disease by producing interferon gamma, which signals through JAK1 and JAK2 to induce CXCL10 and recruit more destructive T cells. This led to JAK inhibitors, including the topical ruxolitinib approval and encouraging oral JAK inhibitor results. The talk then focused on why vitiligo relapses: resident memory T cells persist in the skin and are maintained by IL-15, so blocking IL-15 or its receptor can reduce these cells and may produce more durable responses, though current antibody data are promising but not yet strong enough to rival JAK inhibitors. Finally, the speaker described siRNA therapy as a new platform: chemically modified siRNA can silence JAK1, suppress interferon signaling, and improve vitiligo and alopecia areata in preclinical and early human studies. A delivery system using tiny star-shaped particles may enable topical/trans-epidermal siRNA treatment with long-lasting effects, potentially allowing infrequent dosing and broader skin-disease applications.
View moreConclusions
- Vitiligo is driven primarily by interferon-gamma–activated CD8 T cells rather than the cytokines targeted in other inflammatory skin diseases.
- JAK1/JAK2 signaling is a key downstream pathway in vitiligo, and JAK inhibition can promote repigmentation.
- Topical ruxolitinib and oral JAK inhibitors represent effective emerging treatments, but oral agents may be more potent than current topical approaches.
- Vitiligo relapse after stopping therapy is largely explained by resident memory T cells that persist in the epidermis and re-attack melanocytes.
- Blocking IL-15 can reduce or eliminate these resident memory T cells, offering a strategy for more durable, relapse-resistant control of vitiligo.
- IL-15 blockade shows clinical benefit in trials, but the effect appears modest and may require stronger or more selective targeting to compete with JAK inhibitors.
- The receptor-directed IL-15 strategy may be preferable to cytokine blockade because the receptor is more restricted to T cells and NK cells than IL-15 itself.
- Circulating cytotoxic CD8 T-cell reductions appear to correlate with response to IL-15 blockade, suggesting a plausible mechanism and biomarker of efficacy.
- RNA interference can be turned into a practical drug platform when chemically modified to resist degradation and remain active in vivo.
- JAK1 siRNA can suppress interferon-gamma signaling, reduce vitiligo severity in animal models, and also show activity in alopecia areata models.
- Early human data suggest JAK1-targeting siRNA may produce meaningful hair regrowth with durable effects lasting months after treatment.
- Transepidermal delivery using STAR particles may solve the skin-delivery problem for siRNA and make infrequent topical treatment feasible.
- Overall, the presentation argues that future vitiligo therapy will likely move toward more durable, mechanism-based treatments that either erase pathogenic immune memory or silence key inflammatory genes at the skin level.
- Tang et al. Nat Comm 2023.
- Fakih et al. Nat Comm 2026.
- STAR particles for enhanced topical drug and vaccine delivery.#10.1038/s41591-020-0787-6
- The slide references a New England Journal of Medicine article image related to ruxolitinib cream for vitiligo.